Cargando…

Early‐onset colorectal cancer in young individuals

Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need, especially as diagnosis in this population might lead to the greatest loss of years of life. Since 1994, CRC incidence in individuals younger than 50 years has been increasing by 2% per year. The surge in CRC i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mauri, Gianluca, Sartore‐Bianchi, Andrea, Russo, Antonio‐Giampiero, Marsoni, Silvia, Bardelli, Alberto, Siena, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360363/ https://www.ncbi.nlm.nih.gov/pubmed/30520562 http://dx.doi.org/10.1002/1878-0261.12417

Ejemplares similares

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids
por: Mauri, Gianluca, et al.
Publicado: (2021)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
por: Giannini, Valentina, et al.
Publicado: (2022)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer
por: Durinikova, Erika, et al.
Publicado: (2022)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
por: Rizzetto, Francesco, et al.
Publicado: (2020)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2009)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Exploring the links between cancer and placenta development
por: Costanzo, Vincenzo, et al.
Publicado: (2018)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
por: Patelli, Giorgio, et al.
Publicado: (2021)

Indicators of guideline-concordant care in lung cancer defined with a modified Delphi method and piloted in a cohort of over 5,800 cases
por: Andreano, Anita, et al.
Publicado: (2021)

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
por: Bertotti, Andrea, et al.
Publicado: (2015)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013)

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
por: Normanno, Nicola, et al.
Publicado: (2011)

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review
por: Lombardo, Roberta, et al.
Publicado: (2020)

Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
por: Lorenzato, Annalisa, et al.
Publicado: (2020)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report
por: Mauri, Gianluca, et al.
Publicado: (2023)

Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2011)

Young-onset colorectal cancer risk among individuals with iron-deficiency anaemia and haematochezia
por: Demb, Joshua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e9j9bjrrictfofiiclq4a4ika